Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2968215 | 0.99 | AKT1 (0.62) | AKT1AKT2 | |
| SCHEMBL2976729 | 0.91 | AKT1 (0.52) | AKT1AKT2 | |
| SCHEMBL2964245 | 0.89 | AKT1 (0.55) | AKT1AKT2 | |
| SCHEMBL2979542 | 0.89 | AKT1 (0.57) | AKT1AKT2 | |
| SCHEMBL2963159 | 0.88 | AKT1 (0.56) | AKT1AKT2 | |
| SCHEMBL2970323 | 0.88 | AKT1 (0.52) | AKT1AKT2 | |
| SCHEMBL2962977 | 0.87 | AKT1 (0.71) | AKT1AKT2 | |
| SCHEMBL2970277 | 0.87 | AKT1 (0.55) | AKT1AKT2 | |
| SCHEMBL2975937 | 0.87 | AKT1 (0.51) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL2970738 | 0.87 | AKT1 (0.70) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | claimed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | claimed |
| US-7776864-B2 | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG (DE) | 2010-08-17 | — | — | US | claimed |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-07-22 | — | — | US | claimed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| EP-2050748-A1 | Novel fused pyrimidines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | claimed |
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| US-7776864-B2 | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2188291-A2 | FUSED BICYCLIC PYRIMIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2050748-A1 | Novel fused pyrimidines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009021992-A2 | FUSED BICYCLIC PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | AKT1 9/4885AKT2 4/4885 |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | AKT1 9/4885AKT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.